Sign In
Buy TCMD
$26.43
+0.0700 (+0.266%)
At Close: Jun 16, 2026
Bull Of The Day: Tactile Systems Technology (TCMD)
08:10am, Monday, 18'th Nov 2024
Tactile Systems Technology (TCMD) is a Zacks Rank #2 (Buy) that has an A for Value and a C for Growth. The company develops medical devices for the treatment of chronic diseases at home.
Is Tactile Systems Technology (TCMD) Stock Undervalued Right Now?
10:45am, Tuesday, 12'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Trump's Win and Rate Cut to Benefit Small Businesses: 5 Top Picks
03:01pm, Friday, 08'th Nov 2024
Trump's win and rate cut should benefit small businesses to a good extent. Five small-cap stocks to buy are: PBAM, MAX, TCMD, TZOO, SABK.
Wall Street Analysts Believe Tactile Systems Technology (TCMD) Could Rally 45.9%: Here's is How to Trade
11:00am, Thursday, 07'th Nov 2024
The consensus price target hints at a 45.9% upside potential for Tactile Systems Technology (TCMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Tactile Systems Technology, Inc. (TCMD) Q3 2024 Earnings Call Transcript
06:42pm, Monday, 04'th Nov 2024
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd -
Tactile Systems Technology (TCMD) Tops Q3 Earnings Estimates
06:31pm, Monday, 04'th Nov 2024
Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.85 per share a year ago.
Tactile Systems Technology, Inc. Reports Third Quarter 2024 Financial Results
04:05pm, Monday, 04'th Nov 2024
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people w
Tactile Systems Technology (TCMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Monday, 28'th Oct 2024
Tactile Systems Technology (TCMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Friday, 25'th Oct 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Tactile Medical to Release Third Quarter of Fiscal Year 2024 Financial Results on November 4, 2024
04:05pm, Monday, 21'st Oct 2024
MINNEAPOLIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people w
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Tuesday, 15'th Oct 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
The Future of Medical Devices: Two Strong Buys You Can't Miss
07:00am, Thursday, 10'th Oct 2024
The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs,
Tactile Medical Launches Next-Generation Nimbl™ Lymphedema Platform
08:00am, Wednesday, 02'nd Oct 2024
Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema Initial Launch Focused on Treating Patients Suffering from Upper Extremity Lymphedema
Tactile Medical Stock Rises After Positive Flexitouch Trial Results
12:41pm, Thursday, 26'th Sep 2024
TCMD announces a new study evaluating Flexitouch. The study reveals significant improvements in health-related quality of life and clinical outcomes.
Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study Endpoints Largest U.S. Prospective Clinical T
